Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Weeks ago, Surge Ther­a­peu­tics marked what CEO Michael Gold­berg hopes will go down in his­to­ry as a turn­ing point in can­cer care: the first time a pa­tient re­ceived an im­munother­a­py, in the form of a hy­dro­gel, at the site of their tu­mor dur­ing surgery.

Now, the Cam­bridge, MA-based biotech has raised $32 mil­lion in a Se­ries B to fund that tri­al while bring­ing to the clin­ic two more can­di­dates with the same ap­proach, which it calls in­tra­op­er­a­tive im­munother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER